跳至主要内容

Hybridoma Technology

 Medicilon biology department has established an antibody drug development platform, and our team members have more than 10 years experience in custom antibody production. Medicilon's hybridoma R&D services can provide a variety of immunization methods (proteins, peptides, small molecules, whole cells) to meet with the client's needs.

Development Process of Hybridoma Technology Platform

  • Development Process of Hybridoma Technology Platform
Experimental Timeline
    • 01
      Antigen preparation (provided by the customer or Medicilon)
    • new icon

    • 02
      Standard immunization and serum titer testing
      6-8 weeks
    • new icon

    • 03
      Fusion screening subclones
      4-6 weeks
    • new icon

    • 04
      Providing antibody sequence
      2 weeks
Service Advantage
  • Advanced animal facilities:AAALAC certification;Multiple Immunization methods: Medicilon offers various antigen immunization schemes such as protein, peptide, VLP, whole cell and DNA for antigen preparation;High-throughput screening: FACS, ELISA workstation, Biacore affinity, etc., with high screening efficiency;Comprehensive functional testing services:The functional verification testing platform provides in-vitro pharmacodynamic testing services such as Affinity Ranking, Affinity Measurement, EC50 and IC50, and Cross-reactivity; etc.

Advanced Equipment
  • Hybridoma Technology Advanced Equipment-High throughput screening
    Hybridoma Technology Advanced Equipment-Elisa and Flow Cytometry
    Hybridoma Technology Advanced Equipment-AKTA purification
    Hybridoma Technology Advanced Equipment-Animal immunity: SPF animal lab

评论

此博客中的热门博文

Medicilon and Binhui Biopharmaceutical Have Reached a Strategic Collaboration to Jointly Draw a New Blueprint for the Development of New Biological Drugs

  On March 18, Medicilon and Binhui Biopharmaceutical (Binui Bio) announced a strategic collaboration.  The two parties will work together to jointly explore the possibilities in cutting-edge fields such as oncolytic viruses, nucleic acid drugs and protein drugs. Gather and Work Together to Create Advantages      Facilitate the Research and Development of Oncolytic Viruses, Nucleic Acids, Proteins and Other Drugs As a one-stop biopharmaceutical comprehensive preclinical R&D service CRO, Medicilon has been developing and accumulating for 20 years, always adhering to the spirit of innovation, and has successfully constructed bi/multi-specific antibodies,  ADCs ,  mRNA vaccines ,  small nucleic acid drugs ,  PROTAC , and  CGT technical service platform  that have helped 421 INDs obtain clinical approval.  It is this outstanding achievement that has earned Medicilon wide recognition in the industry and laid a solid foundation f...

A Nickel-Catalyzed Reductive Alkylation of Aryl Bromides and Chlorides for Sp3-Sp2 Bond Formation

  In 2012, a nickel-catalyzed reductive alkylation method of aryl bromides and chlorides was reported. Under the optimized conditions, a variety of aryl and vinyl bromides as well as active aryl chloride can be reductively coupled with alkyl bromides in high yields. The protocols were highly functional-group tolerant and the reactions were not air or moisture sensitive. The reaction showed different chemoselectivity than conventional cross-coupling reactions. Substrates bearing both anelectrophilic and nucleophilic carbon resulted in selective coupling at the electrophilic carbon (R-X) and no reaction occurred at the nucleophilic carbon (R-[M]). The 2010 Nobel Prize in Chemistry was awarded for the Pd-catalyzed cross-coupling, and in the past decade the progress in cross-coupling has not only had a significant impact on academic research but has also influenced the industrial synthetic application. The transition-metal-catalyzed union of nucleophilic organo-boronic acids with elect...

What is Toxicokinetics?

Toxicokinetics  is essentially the study of “how a substance gets into the body and what happens to it in the body”. Four processes are involved in toxicokinetics. The study of the kinetics (movement) of chemicals was originally conducted with pharmaceuticals and thus the term pharmacokinetics became commonly used. In addition, toxicology studies were initially conducted with drugs. However, the science of toxicology has evolved to include environmental and occupational chemicals as well as drugs. Toxicokinetics is thus the appropriate term for the study of the kinetics of all toxic substances. Frequently the terms  toxicokinetics ,  pharmacokinetics , or disposition may be found in the literature to have the same meaning. Disposition is often used in place of toxicokinetics to describe the time-course of movement of chemicals through the body (that is, how does the body dispose of a xenobiotic?). The disposition of a toxicant along with its’ biological reactivi...